Bladder Cancer Therapeutics: A Global Strategic Business Report
San Jose, California (PRWEB) February 22, 2010
Among all the known forms of cancer, bladder cancer is the seventh most common form of cancer that affects people worldwide. Bladder cancer places a significant risk of mortality and morbidity both on patients and the society. The risk of acquiring bladder cancer is high among smokers, aging population, workers at chemical industry, and among people with urinary tract infections. Individuals with a family history of bladder cancer are also more likely to inherit the disease. Patients primarily suffer from bladder cancer in their old ages and thus rise in the aging population group remains a key growth driver for bladder cancer therapeutics.
The United States and European markets dominate the world bladder cancer therapeutics market, as stated by the new market research report on bladder cancer therapeutics market. Bladder cancer is one of the leading types of cancer affecting Americans. Bladder cancer incidence in the US is increasing consistently since the late 1950s, and continues to increase with aging population. However, the incidence and prevalence of bladder cancer is highest in Europe, globally. Tobacco smoking, increased occupational exposure, and Schistosoma haematobium infection are major risk factors for bladder cancer in Europe.
Bladder cancer market presents immense commercial opportunities for the drug developers, specifically to address unmet needs in metastatic condition. Bacillus Calmette-Guerin (BCG) is the most widely used treatment for bladder cancer, and a 'Gold Standard' therapy for non-invasive cancer of the bladder. Newer drugs including Gemzar (Gemcitabine) also received approval for the treatment of superficial bladder cancer, in BCG refractory patients. Though there is no effective treatment for metastatic bladder cancer, more often systemic chemotherapy in combination with multi-agent regimes are used.
Key players profiled in the report include Allergan Inc., Allos Therapeutics Inc., Astellas Pharma Inc, Astrazeneca PLC, BioCancell Therapeutics Inc., Bioniche Life Sciences Inc., Celldex Therapeutics Inc., Cytavis BioPharma GmbH, Eli Lilly and Company, Endo Pharmaceuticals Holdings Inc., F. Hoffmann-La Roche Ltd, Halozyme Therapeutics Inc., Laboratoires Pierre Fabre SA, NatImmune A/S, Nippon Kayaku Co. Ltd, Oncogenex Pharmaceuticals Inc., PharmaMar S.A., Sanofi-Aventis, Spectrum Pharmaceuticals Inc., Telormedix SA, and Viventia Biotechnologies Inc, among others.
The report titled "Bladder Cancer Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, competitive scenario, overview of bladder cancer treatment, product introductions/innovations, and recent industry activity. The study analyzes market data and analytics in terms of value sales for the United States, Japan, Europe, and Rest of World.
For more details about this comprehensive market research report, please visit -
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/